Evaluation of a panel of autoantibody biomarkers for lung cancer
Research type
Research Study
Full title
Nested case-control study to evaluate an autoantibody biomarker panel for the early detection of lung cancer
IRAS ID
197057
Contact name
Usha Menon
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2016/04/27, UCL Data Protection Registration Number
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Despite our improved understanding of cancer biology the number of people being diagnosed with cancer continues to increase. Current global figures estimate 12.7 million new cancer cases and 7.6 million deaths from cancer per year. Survival figures from Cancer Research UK show that the single greatest impact on cancer survival is the stage at which the cancer is detected.
Lung cancer is the most common cancer in the world and the second most common cancer (excluding non-melanoma skin cancer) in the United Kingdom (UK). In the UK around 43,500 people are diagnosed with the disease every year and tragically the majority will lose their lives to this. Lung cancer accounts for one in five of all cancer deaths in the UK with one of the poorest prognoses of all malignant diseases; 75% of patients dying within the first year and less than 10% surviving for five years. This is attributed to the late clinical presentation of the majority of patients with 80% presenting with locally advanced or metastatic disease. The National Lung Screening Trial showed for the first time a significant reduction (20%) in lung cancer specific mortality by screening asymptomatic former or current heavy smokers (aged 55-74) with low dose computed tomography (CT) scanning. The development of a blood-based biomarker would have the potential to focus screening strategies and allow earlier diagnosis with a consequent improvement in treatment outcomes. The aim of this project is to investigate the performance of a promising serum-based biomarker panel of autoantibodies for the earlier diagnosis of lung cancer using the longitudinal pre-diagnosis serum samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) biobank in collaboration with Oncimmune.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
16/SC/0270
Date of REC Opinion
4 May 2016
REC opinion
Favourable Opinion